Contact the Editorial Desk

Correspondence

Aus Peptide is glad to hear about the research record itself: a citation quoted inaccurately, a newly published trial on CJC-1295, ipamorelin, MOTS-c, or sermorelin, or a regulatory update that changes how a compound's status should be described. This is the most useful category of message the dossier receives, and each is read carefully before any change is made to the site.

The most actionable submissions identify the specific page and passage at issue and point to a supporting source — a DOI or PubMed identifier wherever possible — so the proposed correction can be verified against its origin before anything is edited.

Editorial mailbox: editors@auspeptide.com

Outside the dossier

So a message does not go unanswered for the wrong reason, a few categories fall outside what Aus Peptide can take up. This is a dossier of literature, not a clinical service, so it cannot:

• Recommend, evaluate, or comment on a dose, schedule, or route for any individual.
• Advise on whether a research finding applies to a specific person's situation.
• Sell, source, or help locate any compound from any supplier.
• Advise athletes on anti-doping questions, though it will note where a compound is flagged by anti-doping authorities.

Sermorelin should be discussed only with a licensed prescriber; CJC-1295, ipamorelin, and MOTS-c have no approved human use and no clinical-supervision channel to point a reader toward. A reader with clinical questions should consult a licensed healthcare provider in their own jurisdiction. Replies to correspondence are not guaranteed and may lag; the mailbox is checked intermittently.